(Q30241952)

12 June 2017

1 reference

title

PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. (English)

1 reference

12 June 2017

0 references

1 reference

Barbara Gross

1

0 references

Michał Pawlak

object named as

Michal Pawlak

series ordinal

2

0 references

Bart Staels

object named as

Bart Staels

series ordinal

4

0 references

author name string

Philippe Lefebvre

series ordinal

3

1 reference

12 June 2017

16 September 2016

1 reference

Nature Reviews Endocrinology

12 June 2017

1 reference

12 June 2017

13

1 reference

12 June 2017

36-49

1 reference

12 June 2017

1

1 reference

Mechanisms linking obesity with cardiovascular disease

12 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Metabolic nuclear receptor signaling and the inflammatory acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Control of nuclear receptor activities in metabolism by post-translational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Thiazolidinediones and PPARγ agonists: time for a reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Regulation of muscle fiber type and running endurance by PPARdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Physiological functions of peroxisome proliferator-activated receptor β

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Immune regulation of metabolic homeostasis in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Brown adipose tissue: function and physiological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Cold-activated brown adipose tissue in healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Recruited brown adipose tissue as an antiobesity agent in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Brown adipose tissue activation is inversely related to central obesity and metabolic parameters in adult human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Brown adipose tissue activity controls triglyceride clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARγ signaling and metabolism: the good, the bad and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

EBF2 determines and maintains brown adipocyte identity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Transcriptional control of brown fat determination by PRDM16

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Suppression of expression of muscle-associated proteins by PPARalpha in brown adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor α (PPARα) induces PPARγ coactivator 1α (PGC-1α) gene expression and contributes to thermogenic activation of brown fat: involvement of PRDM16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPAR-α agonist elicits metabolically active brown adipocytes and weight loss in diet-induced obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Twist-1 is a PPARdelta-inducible, negative-feedback regulator of PGC-1alpha in brown fat metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARγ and the global map of adipogenesis and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor γ regulates genes involved in insulin/insulin-like growth factor signaling and lipid metabolism during adipogenesis through functionally distinct enhancer classes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Transcription factor cooperativity in early adipogenic hotspots and super-enhancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARγ-induced PARylation promotes local DNA demethylation by production of 5-hydroxymethylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Roles for peroxisome proliferator-activated receptor γ (PPARγ) and PPARγ coactivators 1α and 1β in regulating response of white and brown adipocytes to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

SMRT-GPS2 corepressor pathway dysregulation coincides with obesity-linked adipocyte inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Immune Cell Toll-like Receptor 4 Mediates the Development of Obesity- and Endotoxemia-Associated Adipose Tissue Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPAR-gamma regulates osteoclastogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Differential activation of adipogenesis by multiple PPAR isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARα agonist fenofibrate attenuates TNF-α-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Expression of peroxisome proliferator-activated receptor PPARdelta promotes induction of PPARgamma and adipocyte differentiation in 3T3C2 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor delta (PPARdelta )-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARδ binding to heme oxygenase 1 promoter prevents angiotensin II-induced adipocyte dysfunction in Goldblatt hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Adipocyte SIRT1 knockout promotes PPARγ activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARγ: no SirT, no service.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Browning of human adipocytes requires KLF11 and reprogramming of PPARγ superenhancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Adipose subtype-selective recruitment of TLE3 or Prdm16 by PPARγ specifies lipid storage versus thermogenic gene programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARα and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Activation of PPARdelta alters lipid metabolism in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPAR-β/δ activation promotes phospholipid transfer protein expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Adiponectin, driver or passenger on the road to insulin sensitivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

MitoNEET-mediated effects on browning of white adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARdelta regulates glucose metabolism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Nuclear receptor/microRNA circuitry links muscle fiber type to energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARdelta is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Activation of PPARδ promotes mitochondrial energy metabolism and decreases basal insulin secretion in palmitate-treated β-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Activation of PPARβ/δ protects pancreatic β cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARβ/δ activation induces enteroendocrine L cell GLP-1 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARβ/δ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARβ/δ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Nuclear receptor PPARγ-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Reprogramming of the circadian clock by nutritional challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

The activation of peroxisome proliferator-activated receptor γ is regulated by Krüppel-like transcription factors 6 & 9 under steatotic conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Nuclear receptor atlas of female mouse liver parenchymal, endothelial, and Kupffer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Adiponectin regulation of stellate cell activation via PPARγ-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and liver fibrosis by epigenetically regulating peroxisome proliferator-activated receptor γ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Hepatic lipid accumulation alters global histone h3 lysine 9 and 4 trimethylation in the peroxisome proliferator-activated receptor alpha network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Ketone Body Therapy Protects From Lipotoxicity and Acute Liver Failure Upon Pparα Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PPAR gamma and human metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Pioglitazone use and risk of bladder cancer: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Saroglitazar for the treatment of dyslipidemia in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

PGC1α expression is controlled in skeletal muscles by PPARβ, whose ablation results in fiber-type switching, obesity, and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and Refeeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Dual functions of TAF7L in adipocyte differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Growth differentiation factor 11 is a protective factor for osteoblastogenesis by targeting PPARgamma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

Pharmacological activation of peroxisome proliferator-activated receptor δ improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.135

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2016.135

1 reference

12 June 2017

1 reference

PubMed ID

27636730